BioElectronics Corporation (https://www.bielcorp.com/)(OTC: BIEL) has announced that its strategic distribution and licensing agreement with Electrome Corporation has officially entered the execution phase, with manufacturing now underway for the launch of the company's flagship pulsed shortwave therapy as part of the Electrome PAINKILLER platform. This milestone marks a significant step in the commercialization of BioElectronics' drug-free pain relief technology across North America.
Under the agreement, Electrome will market and distribute BioElectronics' FDA-cleared pulsed shortwave therapy products, including ActiPatch and other products in the BioElectronics portfolio. Electrome is building a comprehensive AI-native pain management platform that integrates advanced artificial intelligence, intelligent automation, predictive analytics, and high-performance digital marketing into a unified consumer ecosystem. This platform is designed to rapidly scale awareness, customer acquisition, and long-term engagement with non-pharmaceutical pain management solutions.
Kelly Whelan, President of BioElectronics Corporation, expressed enthusiasm about the partnership: “We are excited to officially begin the commercial phase of this relationship with Electrome. The receipt of the initial purchase order and the commencement of manufacturing represent important operational milestones. Electrome has assembled an ambitious go-to-market strategy utilizing modern AI-driven technologies and sophisticated direct-response marketing systems that we believe position this partnership for significant growth.”
Electrome's planned rollout will focus heavily on consumer education, digital outreach, scalable ecommerce infrastructure, and AI-enhanced customer engagement systems designed to streamline the consumer purchasing experience while increasing awareness of non-drug pain management solutions. Ken Mayer, CEO of Electrome Corporation, said: “This is an exciting moment for both organizations. We believe BioElectronics' technology represents a compelling opportunity within the rapidly growing non-pharmaceutical pain management market. Our team has been preparing an advanced marketing and ecommerce ecosystem designed to support scalable growth and broad consumer adoption.”
BioElectronics' pulsed shortwave therapy technology provides drug-free, non-invasive pain relief through a wearable therapy platform cleared by the U.S. FDA for the adjunctive treatment of musculoskeletal pain. The technology has been studied across multiple clinical applications and is designed for extended home use without drugs or invasive procedures. Manufacturing activities are currently underway, with commercial launch preparations continuing across branding, ecommerce, logistics, customer support, and digital marketing initiatives.
This partnership is significant because it leverages Electrome's AI-driven marketing capabilities to accelerate the adoption of non-pharmaceutical pain management alternatives, addressing the growing demand for drug-free therapies amid concerns over opioid addiction and side effects of conventional pain medications. The success of this rollout could pave the way for broader acceptance of bioelectronic therapies in the consumer market.
